Working together to advance the treatment of hematologic malignancies, improve quality of life, and better patient outcomes.

Research is at the heart of healthcare innovation, and the 2023 Lymphoma, Leukemia & Myeloma Congress translated the latest research into practical application and treatment strategies for day-to-day practice.

The 2023 Congress was held October 18-21 at the Sheraton New York Times Square Hotel in New York City, where more than 75 experts from around the globe gathered to present the latest clinical evidence, learn optimal treatment strategies, and share best practices with one of the largest live audiences in the field. A pillar in the field of hematologic oncology education, LL&M Congress has stood for more than two decades as the premier gathering dedicated to blood cancers. 

Each year, we honor the leading researchers advancing the field as part of the LL&M Congress awards. Abstracts presented at LL&M are accepted for presentation in categories including Acute Leukemia & Myeloproliferative/Myelodysplastic Diseases, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma.

Our 2023 award recipients include:

  • The SASS Foundation for Medical Research Award: Michaeli Award for Making Contributions to Myeloma Research
    Recipient: Angela Dispenzieri, MD, professor of medicine and of laboratory medicine at the Mayo Clinic, past president of the International Society of Amyloidosis, and president elect for the International Kidney and Monoclonal Gammopathy Group. Dr. Dispenzieri’s award lecture, “POEMS – A Disease Model Biology and Treatment,” focused on multiple myeloma.  

     Three people standing and smiling
  • The SASS Foundation for Medical Research Award: John Ultmann Award for Major Contributions to Lymphoma Research
    Recipient: Julie Vose, MD, MBA, the Neumann M. and Mildred E. Harris Professor and Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center, and former president of the American Society of Clinical Oncology (ASCO). Dr. Vose’s award lecture was “T Cell Lymphomas – How Can We Improve Outcomes beyond Chop?”
     Julie Vose
  • The Bruce Waterfall Memorial Lecture
    Recipient: Morie A. Gertz, MD, MACP, the Roland Seidler Jr. Professor of the Art of Medicine and Chair Emeritus of the Department of Internal Medicine at the Mayo Clinic, where he has served as chair of the division of Hematology and chair of the Department of Medicine. Dr. Gertz’s award lecture was “When to Treat Waldenstrom’s Macroglobulinemia? How to Sequence Medicine.”
     Morie Gertz
  • The Prince Family Lecture
    Recipient: Matthew S. Davids, MD, MMSc, attending physician in the Division of Lymphoma, where he serves as the Director of Clinical Research, as well as Associate Director of the CLL Center. He is also an associate professor of medicine at Harvard Medical School and attends on the inpatient hematologic malignancies service at Brigham and Women's Hospital. Dr. Davids’ award lecture was “BCL2 in CLL: Function, Targeting, and Resistance.”
     Matthew Davids
  • The Rai Lecture
    Recipient: Neil E. Kay, MD, professor of medicine, staff consultant, and career scientist in the Division of Hematology, Department of Medicine, at the Mayo Clinic. He is also a member of the Eastern Cooperative Oncology Group where he is a core leukemia committee member and a member of the National Cancer Institute leukemia steering committee. Dr. Kay’s lecture was “Pathobiology and Management of Double Refractory CLL.”
     Neil Kay


By bringing together the world’s leading educators to discuss the latest scientific advances, we equip healthcare professionals with the tools to advance the treatment of hematologic malignancies, improve quality of life, and better patient outcomes.

All abstracts accepted for LL&M will be published in the American Journal of Hematology, and will also be featured on the new Lymphoma, Leukemia & Myeloma Network, a centralized digital platform for clinicians to access the latest treatment strategies and in-depth learning that covers all areas of blood cancer.

For more information, visit